COVID-19 和呼吸功能不全患者的低剂量全肺放射治疗 (VENTED)
Vented COVID:使用超低剂量双侧全肺放射治疗治疗 COVID-19 呼吸功能受损的危重患者的 II 期研究
胸部 X 光检查形式的低剂量辐射已被用于治疗肺炎患者。 发现这种治疗通过减少炎症和最小的副作用是有效的。 然而,这是一种昂贵的治疗方法,最终被抗生素等成本较低的治疗方法所取代。 一些动物实验也表明辐射可以减少某些类型的炎症。
一些被诊断出患有 COVID-19 肺炎的患者会出现病情恶化,可能会变得非常严重,需要使用呼吸机。 这是由病毒和免疫系统引起的肺部炎症引起的。 对于这项研究,给予的 X 射线称为放射治疗。 放射治疗使用来自大型机器的高能 X 射线束瞄准肺部并减少炎症。 通常,它以更高的剂量给药以治疗癌症。
这项研究的目的是找出对肺部进行一次低剂量 X 射线治疗是否可以减少 COVID-19 感染引起的肺部炎症,这可以帮助患者在不使用呼吸机的情况下呼吸呼吸机。
研究概览
详细说明
主要结果是基于 ICU 的机械通气开始后 30 天的死亡率。根据现有数据,在当前设计中假定通气患者的死亡率为 80%。 在 16 名可评估患者接受超低剂量全肺放射治疗 (ULD-WLRT) 后,将进行中期无效性分析。 如果至少有 3 名患者存活至少 30 天,我们将招募另外 8 名患者(总共 24 名患者)。 否则,试验将停止进行进一步评估。 由于当地机构目前可获得的30天死亡率数据有限,我们将在有数据时回顾性评估我机构未进行ULD-WLRT的机械通气患者的死亡率。
事件次要目标的时间(例如 总生存期、出院时间)分析将使用 Kaplan-Meier 生存分析和竞争风险模型(因死亡而退出研究)进行,包括模型中人口统计学/临床特征的影响。 比例终点(例如停止使用呼吸机的患者百分比)将与 95% Clopper-Pearson 精确置信区间一起计算。 前/后测量将使用线性混合模型进行评估以进行重复测量(根据需要进行适当的数据转换)。 人口统计学/临床特征与其他次要目标(例如磨玻璃混浊 (GGO)/混浊的大小)之间的关联将通过广义线性模型来实现。
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Ohio
-
Columbus、Ohio、美国、43210
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
- 注册后 14 天内的 COVID-19 实验室诊断。
- 入组后 5 天内出现典型 COVID-19 肺炎的 CT 或影像学表现
- 接受基于 ICU 的机械通气
- 预期寿命 ≥ 24 小时,由研究者判断
- 低氧血症定义为 Pa/FIO2 比率 < 300 或 SpO2/FiO2 < 315
- 由患者或其法定/授权代表签署的知情同意书
排除标准:
- 根据研究者和治疗团队的判断,生命垂危,预计生存时间 < 24 小时
- 由于 COVID 感染前存在慢性疾病,预计生存期 < 30 天,由研究者和治疗团队判断
- 患者或法定代表未承诺接受完整的疾病特异性治疗,即舒适护理(允许 DNRCCA)
- 最近 30 天内接受过免疫抑制药物治疗(允许使用类固醇治疗急性呼吸窘迫综合征或感染性休克)
- 假定 COVID 相关疾病超过 14 天
- 住院时间超过 14 天
- 患者被认为不适合进行放射治疗旅行
- 基线时需要补充氧气的慢性低氧血症
- 有记录的活动性结缔组织病(硬皮病)或特发性肺纤维化
- 入组后 365 天内既往放射治疗史导致≥2 级放射性肺炎
- 入组后 180 天内完成胸部放射治疗或既往放射史(可接受皮肤或仅表面皮肤治疗)
- 已知活动性不受控制的肺部细菌或真菌感染。
- 活性细胞毒化疗
- 怀孕或妊娠试验呈阳性的女性
- 母乳喂养
- 注意:在临床试验中或作为标准疗法同时给予恢复期免疫血浆疗法不是排除标准,但会注明
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Radiation Arm
Each subject will receive a dose of whole lung radiation.
A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
|
患者将以一种简化的方式接受双侧肺部 80 cGy 的单剂量治疗,以便可以在一个疗程中快速设计和递送。
该协议中没有使用特定的正常组织约束。
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mortality Rate of Subjects Treated With Whole Lung Low-dose Radiation.
大体时间:up to 1 month post radiation dose
|
Number of subjects who expire from the date of radiation up to 1 month post radiation dose.
The date will be collected if subject expires
|
up to 1 month post radiation dose
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To Compare Total Hospital Stay and Length of Hospital Stay After Post Radiation Dose
大体时间:Until subject discharged for any reason, up to day 47
|
number of days hospitalized before and after radiation
|
Until subject discharged for any reason, up to day 47
|
|
Evaluate Total and Post-ULD-WLRT ICU Length of Stay
大体时间:Until subject discharged for any reason, up to day 47
|
Number of days in ICU after receiving radiation therapy
|
Until subject discharged for any reason, up to day 47
|
|
Number of Days Alive After RT in Days
大体时间:long term follow, up to 277 days
|
Number of days subject survives Ultra Low Dose-Whole Lung Radiation Therapy, including hospital days and post discharge from hospital until lost to follow-up
|
long term follow, up to 277 days
|
|
Days of Supplemental Oxygen Therapy
大体时间:length of hospital stay, up to day 47
|
To evaluate total supplemental oxygen therapy
|
length of hospital stay, up to day 47
|
|
Ventilator-free Days
大体时间:length of subject hospitalization, up to day 47
|
number of days without mechanical ventilation
|
length of subject hospitalization, up to day 47
|
|
Oxygenation Index Post RT
大体时间:length of hospitalization, up to 47 days
|
Oxygenation index until extubated, for up to 47 days. Oxygenation Index (OI) in medicine (OI = FiO2 x MAP x100/ PaO2) assesses severe lung injury, with higher numbers meaning worse function. This is expressed as a fraction, with no units and is not a percentage A normal Oxygenation Index (OI) measures the severity of respiratory failure. The ratio is for a healthy peron is 25 and lower. Oxygenation Index values of 25-40 indicate high mortality, Definitions: Mean Airway Pressure (MAP); FiO2 (Fraction of Inspired Oxygen) is the concentration or percentage of oxygen a patient breathes; PaO2 (Partial pressure of oxygen) is a measurement from an Arterial Blood Gas (ABG) test that shows the pressure of oxygen dissolved in your arterial blood |
length of hospitalization, up to 47 days
|
|
Differences Between Ground Glass Opacities (GGO), Lung Infiltrates and Opacification Percentage
大体时间:assessed at day 0, 7, 14, and 28 post radiation
|
Quantitate post-ULD-WLRT the baseline and Day 7, 14, and 28 CT chest findings ( total number of GGO, lung infiltrates and opacification) and the percentage of each chest finding (GGO, lung infiltrates and opacification) found in a CT scan image.
|
assessed at day 0, 7, 14, and 28 post radiation
|
|
Viral Titers at Days 0, 1 7, 14 and 28 Post RT
大体时间:assessed at days 0, 1, 7, 14 and 28 days post radiation
|
Evaluate SARS-CoV2 viral titers at baseline and post Ultra Low Dose-Whole Lung Radiation Therapy (ULD-WLRT) at Day 0, 1, 7, 14, and 28
|
assessed at days 0, 1, 7, 14 and 28 days post radiation
|
|
Tolerability of Regimen
大体时间:up to 9 months post radiation
|
Establish safety and tolerability using number of days of survival
|
up to 9 months post radiation
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Molecular Markers
大体时间:assessed at days 0, 1, 7, 14, and 28
|
Molecular biomarker levels in COVID-19 patients upfront as well as after treatment with Ultra Low Dose-Whole Lung Radiation Therapy (ULD-WLRT) such as levels or inflammatory and DNA damage markers).
|
assessed at days 0, 1, 7, 14, and 28
|
|
Baseline Molecular Biomarkers
大体时间:during hospitalization, on day 1 prior to radiation
|
Determine baseline molecular biomarkers that predict response to Ultra Low Dose-Whole Lung Radiation Therapy (ULD-WLRT) in COVID-19 patients.
|
during hospitalization, on day 1 prior to radiation
|
|
Molecular Biomarker Level
大体时间:during hospitalization, on days 0, 1, 7, 14, and 28
|
Determine molecular biomarkers that change over the treatment course, correlating with disease status and resolution.
|
during hospitalization, on days 0, 1, 7, 14, and 28
|
|
Evaluate Treatment Plan Evaluation Using CBCT Images
大体时间:day of radiation treatment
|
Retrospectively evaluate rapidly planned treatment using volumetric treatment plan evaluation based on Cone Beam CT (CBCT)
|
day of radiation treatment
|
|
Compare Imaging Data
大体时间:up to 277 days post treatment
|
comparison of raw diagnostic and CBCT imaging data for machine-learning assessment of longitudinal progression in patients with COVID-19
|
up to 277 days post treatment
|
|
Compare Raw Imaging Data for Diagnosis
大体时间:imaging prior to radiation
|
Collect raw imaging data for further evaluation of the potential for identification of COVID-19 in diagnostic scans
|
imaging prior to radiation
|
合作者和调查者
调查人员
- 首席研究员:Arnab Chakravarti、James Cancer Hospital, Department of Radiation Oncology
出版物和有用的链接
一般刊物
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
- Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4. Epub 2020 Feb 24.
- Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today? Yale J Biol Med. 2013 Dec 13;86(4):555-70.
- Calabrese EJ, Dhawan G, Kapoor R, Kozumbo WJ. Radiotherapy treatment of human inflammatory diseases and conditions: Optimal dose. Hum Exp Toxicol. 2019 Aug;38(8):888-898. doi: 10.1177/0960327119846925. Epub 2019 May 6.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
- Rodel F, Keilholz L, Herrmann M, Sauer R, Hildebrandt G. Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy. Int J Radiat Biol. 2007 Jun;83(6):357-66. doi: 10.1080/09553000701317358.
- Schaue D, Jahns J, Hildebrandt G, Trott KR. Radiation treatment of acute inflammation in mice. Int J Radiat Biol. 2005 Sep;81(9):657-67. doi: 10.1080/09553000500385556.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.